15 results about "Dipeptidyl peptidase" patented technology

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The application belongs to the technical field of biotechnology, and particularly relates to application of albumin polypeptide gel beads in a product for treating or preventing sarcopenia. Egg white protein is used as raw material to extract protein, and albumin dipeptide-based peptidase-IV inhibitory peptide is prepared through a biological enzymolysis method. Bioinformatics analysis is used to screen out the inhibitory peptide TPYMFP, and the IC50 value of the inhibitory peptide TPYMFP for dipeptide-based peptidase-IV reaches 3.12 ± 0.49 mmol / L. Further, the optimal preparation conditions of sodium alginate SA and carboxymethyl chitosan CMCS-based gel beads CMCS / SA / TPYMFP are explored. When the SA concentration is 1.5% (w / v), the CMCS concentration is 0.5% (w / v), and the CaCl2 concentration is 1% (w / v), the polypeptide encapsulation rate is increased to 98.26% ± 0.25%. It is verified that the albumin polypeptide gel beads have good pH response characteristics, and efficient protection and intestinal target delivery of the sarcopenia inhibitory peptide are realized. The albumin polypeptide gel beads are applied to preparation of a product for treating or preventing sarcopenia, or in preparation of a related product for increasing muscle mass and strength.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

The present invention is directed to a compound of structural formula I as inhibitor of the dipeptidyl peptidase-IV enzyme and which is useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising the compound and their use in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts or deuterated forms thereof, wherein ring A, R 1 、 R 2 、 R 3 、 R 4 、 and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt or deuterated form thereof, for example, in the treatment of a disease that can be treated by administration of a DPP1 inhibitor.(I)

This invention provides a soybean protein hypoglycemic peptide and its application, belonging to the field of bioactive peptide technology. The sequence of the soybean protein hypoglycemic peptide of this invention is shown as DYPAY or DFPALR. The bioactive peptides DYPAY or DFPALR obtained by screening in this invention exhibit significant dipeptidyl peptidase-IV (DPP-IV) inhibitory activity, effectively increasing the level of endogenous glucagon-like peptide-1 (GLP-1), thereby achieving mechanistic regulation of blood glucose with a clearly defined target. The bioactive peptides of this invention have a clear source, simple structure, are easy to synthesize, and possess good stability and safety, making them suitable for developing functional foods or hypoglycemic-related products, with broad application prospects.

This disclosure relates to the use of compounds and pharmaceutical compositions thereof in the preparation of medicaments for the prevention and / or treatment of myopia. The compounds disclosed herein are medicaments for treating diabetes, selected from at least one of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, insulin sensitizers, or dipeptidyl peptidase-4 inhibitors. This disclosure provides novel compounds for the prevention and / or treatment of myopia, and to further improve efficacy, this disclosure also provides pharmaceutical compositions comprising said compounds.

Composition for use in the prevention and / or in the treatment of intellectual disability and neurodegenerative diseases in a subject with Down syndrome, wherein the composition comprises as an active agent at least one compound belonging to the class of dipeptidyl-peptidase IV (DPP4) enzyme inhibitors and also to the class of gliptins.

Provided herein are compounds of Formula (A'), (A), (I), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (II), (II-A), (II-B), II-D-1), (II-D-2), (II-D-3), (II-D-4), (II-D-4'), (II-D-4''), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (III), (B), (B-I), or (B-I), or Tables A-D, or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising the compound and methods of using the compound, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

Nitrile derivative compounds represented by Chemical Formula I, stereoisomers thereof, deuteration products, cocrystals, solvates, or pharmaceutically acceptable salts are provided, wherein each group is defined as in the detailed description. The compounds have dipeptidyl peptidase 1 inhibitory activity and can be used to manufacture drugs for treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, chronic obstructive pulmonary disease and other diseases. [Chemical Formula I]

This invention discloses a high-yield, dual-effect earthworm protein small molecule peptide and its preparation method, specifically relating to the field of biomedical technology. The preparation method includes: S1, synergistic enzymatic hydrolysis: earthworm protein undergoes autolysis, followed by enzymatic hydrolysis with a complex enzyme of flavor protease and alkaline protease; S2, charge-size bi-stage membrane separation: the hydrolysate is sequentially passed through a 5kDa first-stage ultrafiltration membrane and a 1kDa second-stage ultrafiltration membrane modified with a positive charge; S3, dual-activity-guided purification: using anticoagulant activity and dipeptidyl peptidase-IV inhibitory activity as tracking indicators, the highly active components are collected. The small molecule peptide obtained by this invention has a molecular weight of 400-800 Da, contains novel sequences shown in SEQ ID NO:1 and SEQ ID NO:2, and simultaneously possesses anticoagulant activity and DPP-IV inhibitory activity, with a yield of 17.2-19.1%, which is more than 30% higher than conventional methods. The process of this invention is stable and has good prospects for industrialization.

This invention discloses an egg white-derived dipeptidyl peptidase-4 (DPP-IV) inhibitory peptide and its applications. The amino acid sequence of the inhibitory peptide is shown in SEQ ID NO. 5. This invention utilizes probiotic intervention in laying ducks to expand the peptide profile of egg white, combined with enzymatic digestion, mass spectrometry identification, toxicity prediction, structural feature screening, and molecular docking to obtain the aforementioned peptide. In vitro activity verification shows that this peptide inhibits DPP-IV at a concentration of 2 mg / mL by 71.34 ± 1.62%, significantly better than other homologous peptides. This DPP-IV inhibitory peptide is safe in origin and exhibits outstanding activity, making it suitable for preparing adjunctive hypoglycemic drugs.

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt, a stereoisomer, or a deuterated form thereof, wherein ring A, R1, R2, R4, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.